Key regulator that induces cancerkilling capacity in T cells under hypoxia is identified

Dec 13, 2024

Immune checkpoint blockades, or ICBs, have revolutionized treatment for various advanced cancers. However, their effectiveness has plateaued due to therapeutic resistance that renders tumor-infiltrating lymphocytes, or TILs, ineffective. Thus, finding ways to disarm that resistance and rejuvenate anti-cancer TILs so they can kill tumor cells is an important goal for cancer clinicians.